Shots:

• Part A of the P-II (EMPATHY) trial evaluates ensovibep (75/225/600mg, IV) vs PBO in 407 patients with COVID-19
• The trial met the 1EPs i.e., reduction in viral load @8days for all doses. The 2EPs includes hospitalization, ER visits related to COVID-19, or death, 78% reduction in risk of events, no deaths in patients treated with ensovibep while all doses were well-tolerated with no safety issues
• Novartis will exercise its option to in-license ensovibep, accelerate manufacturing & plans to seek expedited regulatory authorizations globally through US FDA’s EUA while Molecular Partners will receive a $162.85M milestones along with 22% royalty on sales of ensovibep in commercial territories

Ref: Novartis | Image: Novartis